Exo Therapeutics
7 known investors
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
Founders & leadership
DL
David Liu, PhDFounder
AS
Alan Saghatelian, PhDCo-Founder
DL
David Liu
AS
Alan Saghetelian
Investors · 7
Competitors · 2
by search overlap
Exo Imaging23 shared keywordsExo is a company backed by leading venture capital and corporate investors focused on innovative technologies, with particular emphasis on healthcare, bioelectronic medicines, materials science, and deep technology solutions.
Lexeotx11 shared keywordsLEXEO Therapeutics develops gene therapy candidates aimed at genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. The clinical-stage company builds on research from Weill Cornell Medicine and the University of California San Diego.
Companies competing with Exo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Exo Therapeutics do?
- Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
- Who founded Exo Therapeutics?
- Exo Therapeutics was founded by David Liu, PhD, Alan Saghatelian, PhD, David Liu, Alan Saghetelian.
- Who are Exo Therapeutics's investors?
- Exo Therapeutics's investors include Newpath Partners, CRV (Charles River Ventures), Nextech Invest, Raptor Group, Samsara BioCapital, Casdin Capital, Novartis Venture Fund.